If you or a loved one is advised a liver transplant, one of the first steps is a set of blood tests—commonly LFT, KFT, and CBC. For most people, these abbreviations feel confusing, and the reports seem difficult to interpret.
This guide explains what these tests actually mean, why each parameter matters, and how transplant teams use them to plan the safest and most effective treatment.
At high-volume centers such as Medanta – The Medicity, Gurugram, pre-transplant diagnostics form the backbone of outcomes, guiding timing, surgical risk, and perioperative optimization.
Why Pre-Transplant Blood Tests Are Critical
In patients with cirrhosis, acute liver failure, or hepatocellular carcinoma (HCC), these tests provide a real-time snapshot of organ function.
They help determine:
- Severity of liver failure and urgency of transplant
- Kidney function and risk of hepatorenal syndrome or acute kidney injury (AKI)
- Presence of anemia, infection, or bleeding risk
- MELD-Na score, which determines transplant priority
- Overall fitness for major surgery
LFT (Liver Function Test): Understanding Liver Status
LFT is a panel of markers reflecting hepatocellular injury, cholestasis, and synthetic function.
Key Parameters and Interpretation
- Total Bilirubin (0.2–1.2 mg/dL): Elevated levels indicate impaired excretion or severe liver dysfunction
- Direct Bilirubin (0–0.3 mg/dL): Suggests cholestasis or hepatocellular injury when raised
- AST (10–40 U/L) and ALT (7–56 U/L): Reflect hepatocyte injury; ALT is more liver-specific
- ALP (40–130 U/L): Elevated in cholestasis, biliary obstruction, or infiltrative disease
- GGT (8–60 U/L): Sensitive marker for cholestasis and alcohol-related injury
- Serum Albumin (3.5–5.0 g/dL): Low levels reflect poor synthetic function and chronic disease
- INR (0.8–1.2): Elevated INR indicates impaired clotting factor synthesis
What Transplant Teams Focus On
Serum bilirubin, INR, and creatinine (from KFT) form the core of the MELD-Na score. Albumin, while not part of MELD, remains a strong indicator of chronic synthetic failure and nutritional status.
- INR >1.5 suggests clinically significant coagulopathy
- Albumin <2.8–3.0 g/dL reflects advanced disease and worse perioperative reserve
KFT (Kidney Function Test): The Liver–Kidney Connection
Renal dysfunction is common in advanced liver disease and significantly affects outcomes.
Key Parameters
- Serum Creatinine (0.6–1.2 mg/dL): Central to MELD-Na; even small rises are prognostically significant
- Blood Urea Nitrogen (7–20 mg/dL): Supports assessment of renal function and catabolic state
- eGFR (>60 mL/min/1.73 m²): Persistent <30 raises concern for chronic kidney disease
- Serum Sodium (135–145 mEq/L): Hyponatremia reflects advanced portal hypertension and worsens prognosis
- Serum Potassium (3.5–5.0 mEq/L): Critical for perioperative cardiac stability
Clinical Relevance
- Hepatorenal syndrome (HRS-AKI) is now defined using dynamic creatinine changes rather than fixed thresholds
- MELD-Na incorporates sodium, improving mortality prediction over traditional MELD
- Significant renal dysfunction may prompt evaluation for simultaneous liver–kidney transplant (SLKT), based on duration and reversibility criteria
CBC (Complete Blood Count): Detecting Hidden Risks
CBC assesses oxygen-carrying capacity, immune status, and bleeding risk.
Key Parameters
- Hemoglobin: Men 13–17 g/dL; Women 12–15 g/dL → anemia is common and may require optimization
- Hematocrit: Reflects oxygen delivery capacity
- WBC (4,000–11,000/µL): Elevated in infection; low counts may occur in hypersplenism or advanced disease
- Platelets (150,000–450,000/µL): Frequently reduced due to portal hypertension and splenic sequestration
- MCV (80–100 fL): Macrocytosis seen in alcohol-related disease; microcytosis in iron deficiency
- Neutrophils: Elevated counts may indicate active infection requiring control before transplant
Thrombocytopenia: A Key Concern
Platelet counts often fall below 100,000/µL—and sometimes <50,000/µL—in cirrhosis due to splenomegaly and reduced thrombopoietin production. This has direct implications for bleeding risk and intraoperative transfusion planning.
How These Tests Work Together
No single test determines transplant readiness. A composite assessment is essential.
- LFT defines liver injury and synthetic failure; contributes bilirubin and INR to MELD-Na
- KFT identifies renal dysfunction; creatinine and sodium refine urgency and predict outcomes
- CBC detects anemia, infection, and coagulopathy risks that must be corrected preoperatively
The MELD-Na score is calculated using bilirubin, INR, creatinine, and sodium. In general:
- MELD-Na ≥15: Benefit from transplant outweighs risk
- MELD-Na ≥25: High urgency
Imaging (CT, MRI, Doppler) and cardiopulmonary evaluation complement these labs.
Monitoring Before Transplant
Patients on the waiting list undergo repeat testing at intervals based on disease severity:
- Typically every 2–4 weeks
- More frequent (weekly or inpatient monitoring) in unstable or high MELD patients
This dynamic tracking allows timely escalation and transplant planning.
A Note for Liver Cancer (HCC) Patients
In HCC, transplant candidacy depends on both tumor burden and liver function.
In addition to LFT, KFT, and CBC:
- Alpha-fetoprotein (AFP) is monitored
- Imaging defines eligibility (Milan criteria and expanded criteria such as UCSF in selected cases)
When criteria are met, transplantation offers cure by removing both tumor and cirrhotic liver.
Final Thought
LFT, KFT, and CBC are not just lab reports—they are critical signals that guide life-saving decisions. Interpreted together by an experienced multidisciplinary transplant team, they determine not only if a transplant is needed, but when and how it can be performed most safely.
At experienced centers, this integrated approach—combining laboratory data, imaging, and clinical expertise—is what drives consistently strong outcomes in liver transplantation.
